3 Chinese Energy Stocks To Buy And 3 To Avoid


Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week

Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap. In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelic Stock News Stories for the Week of May 17th – 23rd, 2021. Without further ado, let’s get started. 10. Red White & Bloom Announces Successful Launch of High Times THC Products in 23 Michigan Dispensaries With Michigan’s Marijuana Market Continuing its Rapid Rise, the MRA Reported April Sales in the Great Lakes State Reached USD $154 Million, Putting the State’s Cannabis Market on a Current Annualized Run-Rate of USD $1.85 Billion Red White & Bloom (CSE: RWB) (OTCQX: RWBYF) announced on Tuesday the successful launch of the company’s High Times branded THC products in 23 Michigan dispensaries throughout the majority of the Great Lakes State. Within the first two weeks, RWB’s initial CDN $1.25 million order was already 60% sold. As evidence of the popularity of the iconic High Times cannabis brand in Michigan, some retailers saw their High Times THC pre-orders exceed 10% of their dispensary’s total inventory. READ FULL RWB ARTICLE 9. New Field Trip Study Suggests Americans Open to the Idea of Psychedelic Treatments Though There Have Been Positive Stories About Those Who Took Time to Reconnect With Family, Enjoy a Slower Pace of Life, and Exercise More During the Covid Crisis, Over Eight Out of Ten Americans Surveyed By Field Trip Reported at Least One Symptom of Depression The results of Field Trip Health’s (CSE: FTRP) (OTC: FTRPF) first annual “State of Mind” survey hold few surprises for those who have followed the news around the effects of the pandemic on mental health. Field Trip Health is the largest provider of psychedelic therapies in the world and initiated this survey to look into the state of mental and emotional health in the U.S., and to get a sense of how receptive respondents are towards incorporating psychedelics into treatment. READ FULL FTRP ARTICLE 8. Aurora Cannabis to Commence Trading on NASDAQ The Move to the NASDAQ is Reportedly Part of the Firm’s Efforts to Reduce Costs Aurora Cannabis (TSX: ACB) (NYSE: ACB) (FRA: 21P) reported that the company has completed the transfer of its stateside listing to the NASDAQ Global Select Market, from that of the New York Stock Exchange after yesterday’s closing bell. The planned transfer was originally reported on May 13. The company this morning is set to commence trading on the Nasdaq following the transfer while maintaining the symbol “ACB”. READ FULL ACB ARTICLE 7. MindMed Announces the Approval of Mescaline Study Mescaline is a Classic Serotonergic Hallucinogen, Similar to LSD and Psilocybin, With a Long, Non-Regulated History of Spiritual Use MindMed (NEO: MMED) (NASDAQ: MNMD) (FRA: MMQ) announced the approval by the local Swiss ethics committee of the first clinical trial evaluating the acute effects of different doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered states of consciousness (MDR-Study). The study will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland, and is planned to start this month. READ FULL MINDMED ARTICLE 6. Ayr Wellness: Analysts Anticipate US$108 Million in Q3 Revenue Three Analysts Have Revenue Estimates for the Third Quarter, With the Average Projection Coming in at USD $108 Million Ayr Strategies (CSE: AYR.A) (OTCQX: AYRSF) announced that they will be reporting their fiscal third quarter financials after hours on March 26th. Analysts have a consensus C$58 12-month price target on the company, via a total of 4 analysts, with one analyst having a strong buy rating and the other three having buy ratings. The street high comes from Beacon Securities with a C$76 price target. READ FULL AYR ARTICLE 5. Can Psychedelics Actually Cure Depression and PTSD? There is Now Data Suggesting That Magic Mushrooms and Ecstasy — Combined With Talk Therapy — May Help People With Severe Depression and Post-Traumatic Stress Disorder Is there about to be a psychedelic drug boom in mental health treatment? In May researchers released data from a phase 3 trial that used MDMA (street name: ecstasy) along with talk therapy to treat people who have post-traumatic stress disorder (PTSD). And Compass Pathways (NASDAQ: CMPS) is exploring the use of psilocybin (the active ingredient in “magic mushrooms”) in combination with talk therapy, to treat people who have severe depression. READ FULL CMPS ARTICLE 4. Cannabis Co Greenlane Holdings And KushCo Holdings Move a Step Closer to Merger In March, the Companies Announced That KushCo Had Agreed to Become a Wholly-Owned Subsidiary of Greenlane Under an All-Stock Deal Greenlane Holdings (NASDAQ: GNLN) and KushCo Holdings (OTCQX: KSHB) are one step closer to finalizing their recent merger. On Tuesday, the companies reported the expiration of the 30-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for the proposed merger. READ FULL GNLN KSHB ARTICLE 3. Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder Psilocybin Has Been Granted Breakthrough Therapy Designation by the U.S. FDA to Multiple Entities in the USA, and This Specific Trial Will Become the First of its Kind Comparing a 25mg Psilocybin Capsule With Cybin’s Proprietary Sublingual Film Formulation Cybin Inc. (NEO: CYBN) (OTC: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the Institutional Review Board (IRB) at the University of the West Indies Hospital, in Jamaica has granted approval to commence the study of its sublingual psilocybin formulation (CYB001) in a Phase II clinical trial for patients suffering with Major Depressive Disorder (MDD). Commencement of the clinical trial is subject to final confirmation of study material specifications by Jamaica’s Ministry of Health. READ FULL CYBN ARTICLE 2. GrowGeneration Acquires The Harvest Company, Expands Footprint in California’s Emerald Triangle Acquisition Brings Number of GrowGen Locations Nationwide to 55 GrowGeneration (NASDAQ: GRWG), the nation’s largest chain of specialty hydroponic and organic garden centers, today announced its acquisition of The Harvest Company, a northern California-based hydroponic supply center and cultivation design innovator with stores in Redding and Trinity County. The Harvest Company serves growers in Northern California’s Emerald Triangle – the largest cannabis-producing region in the country. READ FULL GRWG ARTICLE 1. MindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome System Using This State-of-the-Art Drug Delivery Technology, MindMed is Seeking to Capitalize on the Opportunity to Mitigate the Serious Side Effects That Can Make Some Orally Administered Psychedelics Poor Drug Candidates MindMed (NEO: MMED) (NASDAQ: MNMD) (FRA: MMQ) and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announced the execution of an MOU regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates, leveraging Nextage’s proprietary Brain Targeting Liposome System (BTLS) delivery technology, for which it has an exclusive license. MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration. READ FULL MMED ARTICLE See more from BenzingaClick here for options trades from BenzingaSt. James Gold Expands its Drilling Exploration in Central NewfoundlandHeadHunter Group: Q1 Earnings Insights© 2021 Benzinga does not provide investment advice. All rights reserved.

What's your reaction?

In Love
Not Sure

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News